Etiology of testosterone deficiency after radical prostatectomy.
리뷰
2/5 보강
TL;DR
Routine androgen surveillance and prospective trials are warranted to refine the timing and long-term outcomes of administering exogenous testosterone post-RP.
OpenAlex 토픽 ·
Hormonal and reproductive studies
Prostate Cancer Treatment and Research
Sexual Differentiation and Disorders
Routine androgen surveillance and prospective trials are warranted to refine the timing and long-term outcomes of administering exogenous testosterone post-RP.
APA
Muhammed A.M. Hammad, Dhiresh Bandaru, et al. (2026). Etiology of testosterone deficiency after radical prostatectomy.. Urologic oncology, 44(5), 111035. https://doi.org/10.1016/j.urolonc.2026.111035
MLA
Muhammed A.M. Hammad, et al.. "Etiology of testosterone deficiency after radical prostatectomy.." Urologic oncology, vol. 44, no. 5, 2026, pp. 111035.
PMID
41775590
Abstract 한글 요약
[INTRODUCTION] Testosterone deficiency (TD) may occur after radical prostatectomy (RP). Guidance on prevalence, mechanisms, and testosterone-replacement therapy (TRT) safety remains limited.
[OBJECTIVE] To summarize contemporary evidence on the etiology of post-RP TD.
[METHODS] A PRISMA-ScR scoping review identified English-language human studies reporting the etiology of post-RP TD. Fourteen of 186 screened articles met the inclusion criteria.
[RESULTS] TD develops in 20% to 30% of men within 4 weeks and persists in 37.5% by day 90. Proposed mechanisms described in the literature include perioperative venous, ischemic, and neuroendocrine perturbations, though supporting evidence remains limited and largely indirect.
[CONCLUSIONS] One-third of men experience transient or persistent TD post-RP owing to venous, ischemic, and endocrine factors; most normalize within a year. Routine androgen surveillance and prospective trials are warranted to refine the timing and long-term outcomes of administering exogenous testosterone post-RP.
[OBJECTIVE] To summarize contemporary evidence on the etiology of post-RP TD.
[METHODS] A PRISMA-ScR scoping review identified English-language human studies reporting the etiology of post-RP TD. Fourteen of 186 screened articles met the inclusion criteria.
[RESULTS] TD develops in 20% to 30% of men within 4 weeks and persists in 37.5% by day 90. Proposed mechanisms described in the literature include perioperative venous, ischemic, and neuroendocrine perturbations, though supporting evidence remains limited and largely indirect.
[CONCLUSIONS] One-third of men experience transient or persistent TD post-RP owing to venous, ischemic, and endocrine factors; most normalize within a year. Routine androgen surveillance and prospective trials are warranted to refine the timing and long-term outcomes of administering exogenous testosterone post-RP.